Have you heard of magic mushroom stocks? Pot stocks gave investors excellent returns in 2020. However, most investors did miss out on this opportunity. For the most part, magic mushrooms are largely illegal in the US, and research has shown the drug’s effectiveness in treating conditions like depression, anxiety, and opioid addiction.
As of late, this industry has been demonstrating its potential. Therefore, it might not be a bad idea to look into the investment world of psychedelics. Psychedelic stocks are in a sector that most people would classify as fast-moving. Many analysts consider this sector as speculative and overpriced.
Chart by TradingView
Table of Contents
Magic Mushroom Stocks Introduction
Psychedelic companies are expected to have an additional price increase in 2021. However, the real money that will be made via psychedelic companies will be via FDA-approved drugs to treat depression and mental health.
While our likelihood of seeing psychedelic products on shelves is low, micro-dosing and psychedelic-assisted therapy are now hitting the mainstream channels.
Quite a few companies have also gained early popularity, like Mind Med, because of who is backing them. With this information in light, let’s look at some Psychedelic stocks that have the potential to go up significantly in value. So, while you can’t trade magic mushroom stocks, you have options.
There are psychedelics you can trade. And there have been studies that something like magic mushrooms can help with medical and mental issues. This, of course, would be done with professionals and not something you get off the street.
Top Psychedelic Stocks
- $MMEDF
- $MYCOF
- $MCURF
- $TWGL
1. Mindmed (OTCQB: MMEDF)
MindMed (OTCQB: MMEDF) is a company that offers a highly diverse range of psychedelic drugs in clinical development and also in R&D. Digital therapeutics are evidence-based therapeutic interventions for patients that help them manage, prevent or treat a mental disorder or disease.
The company has multiple FDA-approved trials underway in numerous jurisdictions and various geographies. Mind medicine aims to use substances like psilocybin, LSD, and also MDMA for harsh psychiatric conditions.
Mind Med is a good company because of its development projects, and it already has a pipeline of early-stage trials underway. However, experienced pharma investors are a little apprehensive because most of the Mind Meds chemicals being developed have already been discovered.
Therefore, they cannot be patented because they were of natural origin or were found long ago by someone else. However, the company will remain top-rated and secure because of all its intellectual property breakthroughs.
Mind Medicine is one of the more advanced companies, but it is severely undervalued in its projects and big-name collaborators. This makes it a good investment because the future growth potential of this medicine is very bright.
2. Mydecine (OTC: MYCOF Stock Report) (CSE: MYCO)
MYCOF stock has been experiencing an upward stock price movement for the last few weeks. The increase in MYCOF stock value can also be attributed to the company’s recent commercial export of legal psilocybin mushrooms to Canada. The company has also completed its recent harvest in its Jamaican facility.
Mushrooms are being used for their compounds, extracted and refined by Mydecine and made available for purchase by other licensed companies. Mydecine is also planning to study the compounds for potential use down the line in psilocybin-assisted psychotherapy for PTSD.
COMPANY |  |  |  |
|---|---|---|---|
| DESCRIPTION | Trade Ideas provides powerful tools like real-time market scanning, AI-driven trade signals, customizable alerts, advanced charting capabilities, and time-saving data visualization | Barchart.com is the leading provider of real-time or delayed intraday stock and commodities charts and quotes. Track and analyze your investments and keep tabs on your portfolio | FinViz is an online stock screening, research, and visualization platform that offers various trading tools on a single platform. Solid scanner for traders or investors |
| HIGHLIGHTS | Trade smarter • Trade faster • Ease of use • Artificial intelligence • Real-time scanning • Customizable Trade Ideas > | Real-time quotes • Equities scanner • Ease of use • Track your investments • Analyze portfolio Barchart > | Stock screener • Powerful research tool • Heat map • Ease of use • Financial visualizations Finviz > |
3. Mind Cure Health Inc. (OTC: MCURF)
MCUR is one of the lesser-discussed magic mushroom stocks; however, the stock has been experiencing higher momentum lately. The penny stock, however, is not traded as frequently as other stocks in its category.
The company has recently announced its psychedelic research program, and the initial focus will be on psilocybin, ketamine, and ibogaine. The company aims to provide its patients with treatments with ketamine and psilocybin.
4. 20/20 Global (OTC Pink: TWGL)
The company is relatively new to the psychedelic world and is a fully reporting issuer to the Securities and Exchange Commission. Ehave is another psychedelic company in digital therapeutics and is developing a ketamine delivery platform that goes by the name of KetaDASH.
They’ve sold 100% of their Mycotia therapies subsidiary to 20/20 Global while acquiring 75% of Global’s outstanding shares. 20/20 Global will look into other business opportunities, including psychedelic retreats and medicinal mushrooms.
5. Havn Life Sciences (CSE: HAVN)
Havn Life Sciences has gained a lot of investor attention and popularity because of the big names it owns. If you talk about the popular names in cannabis, Aphira is likely to be in the top five—the CEO of Aphira Havn. Vic Neufeld is behind Havn Life Sciences.
Havn Life Sciences has also announced a new partnership with veterans mental health non-profit Westwood Institute. This partnership is strategic and aims to work on developing therapy using psychedelics for veterans.
Havn has also recently signed an MOU helping supply products and compounds for use in Heroic Heart’s future clinical studies. The company aims to research and investigate the effect of low-dose psychedelic compounds on veterans suffering from emotional trauma and PTSD.
6. Numinous Wellness (TSX: NUMI)
Numinous Wellness is a company that the Canadian government has recently licensed to cultivate, extract, and sell naturally sourced, sustainable psilocybin, also known as magic mushrooms. They’re also the owner of a dealer’s license.
This means that the company can import, export, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline. Numinus offers three pathways for psychedelic-assisted psychotherapy.
The company has also traded high six-figure and low seven-figure dollar volumes daily. Numinus Wellness has a great business plan and has a couple of credible advisors onboard.
However, it does not file audited financials on the US Securities and Exchange Commission’s EDGAR system.
Final Thoughts: Magic Mushroom Stocks
The magic mushroom stocks industry could be on the brink of a boom, and it might make sense to invest some of your shares into these magic mushroom tocks. The growth charts are positive even if there isn’t a massive price increase, as we predict. There’ll be a substantial price increase, which can help investors turn out a good profit.
The competition between the dozens of biopharmaceutical companies is fierce. Many companies are seeking capital through which they can conduct expensive and lengthy drug trials, develop intellectual property, and help advance the treatment of various mental disorders. Whether you’re day trading or investing, these are options for you.
